Article
Multidisciplinary Sciences
Qingqing Hu, Jiajia Xu, Jingshu Ke, Ziye Zhang, Ting Chu
Summary: This study assessed the adverse events associated with S-1 and 5-fluorouracil (5-FU) and provided focused healthcare approaches to improve patient compliance and quality of survival. The results showed a higher incidence of stomatitis, hypokalemia, mucosal inflammation, and hypophosphatemia in the 5-FU group compared to the S-1 group.
Review
Oncology
Sang-Ho Jeong, Rock Bum Kim, Sung Eun Oh, Ji Yeong An, Kyung Won Seo, Jae-Seok Min
Summary: This study compared the efficacy of S-1 and CAPOX regimens in stage II or III gastric cancer patients. The results showed that there was no significant difference in five-year overall survival (OS) and disease-free survival (DFS) between the two regimens in all stages. This indicates that S-1 and CAPOX regimens have comparable efficacy in treating stage II or III gastric cancer patients.
Review
Biotechnology & Applied Microbiology
Suhana Ahmad, Lidawani Lambuk, Naveed Ahmed, Ali Mussa, Vincent Tee, Ros Akmal Mohd Idris, Nur Fazimah Sahran, Yean Yean Chan, Rosline Hassan, Yeong Yeh Lee, Rohimah Mohamud
Summary: Nab-paclitaxel demonstrates good efficacy and safety in the treatment of metastatic gastric cancer, providing better disease response and longer survival.
Article
Medicine, General & Internal
Jian-Hong Yu, Zao-Zao Wang, Ying-Chong Fan, Mao-Xing Liu, Kai Xu, Nan Zhang, Zhen-Dan Yao, Hong Yang, Cheng-Hai Zhang, Jia-Di Xing, Ming Cui, Xiang-Qian Su
Summary: In comparing neoadjuvant chemotherapy followed by surgery (NACS) with surgery alone (SA) for locally advanced gastric cancer, no significant difference was found in overall survival, but the NACS group had a longer operation time, higher R0 resection rate, lower reoperation rate, and lower anastomotic leakage rate.
CHINESE MEDICAL JOURNAL
(2021)
Article
Oncology
Yoon-Koo Kang, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young-Woo Kim, Jin Young Kim, Min-Hee Ryu, Sun Young Rha, Ik Joo Chung, In-Ho Kim, Sang Cheul Oh, Young Soo Park, Taeil Son, Mi Ran Jung, Mi Hwa Heo, Hark Kyun Kim, ChoHyun Park, Chang Hak Yoo, Jin-Hyuk Choi, Dae Young Zang, You Jin Jang, Ji Young Sul, Jong Gwang Kim, Beom Su Kim, Seung-Hoon Beom, Sang Hee Cho, Seung Wan Ryu, Myeong-Cherl Kook, Baek-Yeol Ryoo, Hyun Ki Kim, Moon-Won Yoo, Nam Su Lee, Sang Ho Lee, Gyunji Kim, YeonJu Lee, Jee Hyun Lee, Sung Hoon Noh
Summary: The PRODIGY study demonstrated that neoadjuvant DOS chemotherapy as part of perioperative chemotherapy is effective and well tolerated in Korean patients with LAGC.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Hung-Hsuan Yen, Chiung-Nien Chen, Chi-Chuan Yeh, I-Rue Lai
Summary: This study compared the characteristics and long-term survival outcomes of gastric cancer patients receiving UFT and S-1 monotherapy, showing similar chemotherapy completion rates and 5-year survival rates in both groups. After adjusting for other factors, the hazard ratio of adjuvant chemotherapy (S-1 versus UFT) on RFS was 1.25.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Qingqian Zhang, Yue Qian, Ying Yin
Summary: This review compared the effects of S-1 and capecitabine-based adjuvant chemotherapy on disease-free survival, overall survival, and adverse events in gastric cancer patients. The study found that both regimens had similar effects and could be used interchangeably as adjuvant treatments.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Oncology
Zev A. Wainberg, Charles S. Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Joseph Chao
Summary: This comprehensive analysis demonstrated consistent improvements towards more favorable clinical outcomes with pembrolizumab across lines of therapy in patients with CPS >= 10 G/GEJ cancer.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Yonghe Chen, Jiasheng He, Dan Liu, Jian Xiao, Xijie Chen, Haijie Tang, Dandong Luo, Chenyu Shang, Lei Lian, Junsheng Peng
Summary: The study found that in patients with locally advanced gastric cancer, there was no significant difference in efficacy between doublet and triplet neoadjuvant chemotherapy regimens in terms of tumor regression, resection rate, and survival. However, the triplet regimen may increase the risk of post-surgery complications, particularly abdominal infections.
Article
Medicine, General & Internal
Qin Tang, Mao Huang, Jing Zhang, Zhen Huang, Linlian Wang, Zhengxin Gong, Liangdan Tang
Summary: This study aimed to compare the survival outcomes and adverse events of HIPEC, IP, and IV chemotherapy for primary advanced ovarian cancer. The results showed that HIPEC2 had a statistically significant OS benefit compared to IV, weekly dose-dense chemotherapy and HIPEC1. Intraperitoneal plus intravenous chemotherapy was associated with a better overall survival likelihood compared to IV. For progression-free survival, HIPEC1 was better than weekly dose-dense chemotherapy. HIPEC may have a higher incidence of electrolyte disturbances (>= grade 3).
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, Research & Experimental
Zhuo Wang, Lihua Dong, Weiyan Shi, Ling Gao, Xin Jiang, Suyang Xue, Pengyu Chang
Summary: This study compared the overall survival, relapse-free survival, and disease-free survival of patients with local-advanced gastric cancer (LAGC) after surgery plus adjuvant therapy and with surgery alone based on a meta-analysis. The results showed that adjuvant therapy led to improved survival in LAGC patients.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Medicine, General & Internal
Jian-Xian Lin, Yi-Hui Tang, Guan-Jie Lin, Yu-Bin Ma, Jacopo Desiderio, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Chao-Hui Zheng, Amilcare Parisi, Mark J. Truty, Chang-Ming Huang
Summary: This cohort study compares the survival rates of patients with locally advanced gastric cancer who received adjuvant chemotherapy (AC) and those who did not after neoadjuvant chemotherapy followed by surgery. The study found that AC was associated with improved survival in patients with a lymph node ratio of at least 9%. These findings suggest that the lymph node ratio could be useful in AC selection for locally advanced gastric cancer in future decision-making processes.
Article
Oncology
Zev A. Wainberg, Jipan Xie, Adriana Valderrama, Lei Yin, Shujing Zhang, Chie-Schin Shih, Pooja Bhagia, Qianqian Gu, Kohei Shitara, Yelena Y. Janjigian, Josep Tabernero
Summary: This study assessed the association between event-free survival (EFS) and overall survival (OS) in the treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma. The results showed that EFS is a good surrogate for OS in this setting. Sensitivity analyses confirmed the findings.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Naomi Takemura, Siu Ling Chan, Robert Smith, Denise Shuk Ting Cheung, Chia-Chin Lin
Summary: This study found that physical activity may be beneficial for reducing mortality risk in advanced cancer patients, although no significant survival improvement was observed in randomized trials. Despite conflicting views, exercise can still be recommended to improve outcomes for advanced cancer patients.
Article
Oncology
Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang
Summary: In patients with metastatic or recurrent gastric cancer, the S-1/oxaliplatin (SOX) regimen showed non-inferiority to the S-1 plus cisplatin (SP) regimen in terms of progression-free survival, with similar overall survival and different toxicity profiles between the two regimens.
Review
Gastroenterology & Hepatology
Yuqin Huang, Sen Wang, Youquan Shi, Dong Tang, Wei Wang, Yang Chong, Huaicheng Zhou, Qingquan Xiong, Jie Wang, Daorong Wang
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2016)
Article
Biotechnology & Applied Microbiology
Xiaolan You, Yuanjie Wang, Jian Wu, Qinghong Liu, Dehu Chen, Dong Tang, Daorong Wang
ONCOTARGETS AND THERAPY
(2018)
Article
Oncology
Xiaolan You, Yuanjie Wang, Jian Wu, Qinghong Liu, Yanqing Liu, Yayun Qian, Jue Chen, Dong Tang, Daorong Wang
Review
Oncology
Dong Tang, Daorong Wang, Zhongxu Yuan, Xiaofeng Xue, Ye Zhang, Yong An, Jianmin Chen, Min Tu, Zipeng Lu, Jishu Wei, Kuirong Jiang, Yi Miao
INTERNATIONAL JOURNAL OF CANCER
(2013)
Review
Oncology
Zhujiang Dai, Jingqiu Zhang, Qi Wu, Juan Chen, Jun Liu, Lu Wang, Chaowu Chen, Jiaming Xu, Hongpeng Zhang, Chunfeng Shi, Zhen Li, Huiwen Fang, Chaobiao Lin, Dong Tang, Daorong Wang
INTERNATIONAL JOURNAL OF CANCER
(2019)
Article
Gastroenterology & Hepatology
Sen Wang, Qingyang Meng, Jun Gao, Yuqin Huang, Jie Wang, Yang Chong, Youquan Shi, Huaicheng Zhou, Wei Wang, Dong Tang, Daorong Wang
GASTROENTEROLOGY RESEARCH AND PRACTICE
(2019)
Article
Biochemistry & Molecular Biology
Sen Wang, Dong Tang, Wei Wang, Yining Yang, Xiaoqing Wu, Liuhua Wang, Daorong Wang
Review
Cell Biology
Zhujiang Dai, Jingqiu Zhang, Qi Wu, Huiwen Fang, Chunfeng Shi, Zhen Li, Chaobiao Lin, Dong Tang, Daorong Wang
CELL COMMUNICATION AND SIGNALING
(2020)
Article
Biotechnology & Applied Microbiology
Ping Li, Liuhua Wang, Pengfei Li, Fangyong Hu, Yi Cao, Dong Tang, Gang Ye, Hongbo Li, Daorong Wang
Summary: This study identified the functional significance of XIST in gastric cancer (GC) progression by showing that XIST elevated EPHA1 expression by recruiting HNF4A. Silencing of XIST inhibited GC progression in vitro and in vivo, while overexpressed XIST and EPHA1 had a reversed effect on cell proliferation and invasion. The study also demonstrated that XIST increases the enrichment of HNF4A in the promoter region of EPHA1, thus promoting the deterioration of GC.
CANCER GENE THERAPY
(2021)